BMC Biology (Sep 2020)

ACBE, a new base editor for simultaneous C-to-T and A-to-G substitutions in mammalian systems

  • Jingke Xie,
  • Xingyun Huang,
  • Xia Wang,
  • Shixue Gou,
  • Yanhui Liang,
  • Fangbing Chen,
  • Nan Li,
  • Zhen Ouyang,
  • Quanjun Zhang,
  • Weikai Ge,
  • Qin Jin,
  • Hui Shi,
  • Zhenpeng Zhuang,
  • Xiaozhu Zhao,
  • Meng Lian,
  • Jiaowei Wang,
  • Yinghua Ye,
  • Longquan Quan,
  • Han Wu,
  • Kepin Wang,
  • Liangxue Lai

DOI
https://doi.org/10.1186/s12915-020-00866-5
Journal volume & issue
Vol. 18, no. 1
pp. 1 – 14

Abstract

Read online

Abstract Background Many favorable traits of crops and livestock and human genetic diseases arise from multiple single nucleotide polymorphisms or multiple point mutations with heterogeneous base substitutions at the same locus. Current cytosine or adenine base editors can only accomplish C-to-T (G-to-A) or A-to-G (T-to-C) substitutions in the windows of target genomic sites of organisms; therefore, there is a need to develop base editors that can simultaneously achieve C-to-T and A-to-G substitutions at the targeting site. Results In this study, a novel fusion adenine and cytosine base editor (ACBE) was generated by fusing a heterodimer of TadA (ecTadAWT/*) and an activation-induced cytidine deaminase (AID) to the N- and C-terminals of Cas9 nickase (nCas9), respectively. ACBE could simultaneously induce C-to-T and A-to-G base editing at the same target site, which were verified in HEK293-EGFP reporter cell line and 45 endogenous gene loci of HEK293 cells. Moreover, the ACBE could accomplish simultaneous point mutations of C-to-T and A-to-G in primary somatic cells (mouse embryonic fibroblasts and porcine fetal fibroblasts) in an applicable efficiency. Furthermore, the spacer length of sgRNA and the length of linker could influence the dual base editing activity, which provided a direction to optimize the ACBE system. Conclusion The newly developed ACBE would expand base editor toolkits and should promote the generation of animals and the gene therapy of genetic diseases with heterogeneous point mutations.

Keywords